Shared more. Cited more. Safe forever.
    • advanced search
    • submit works
    • about
    • help
    • contact us
    • login
    View Item 
    •   MOspace Home
    • University of Missouri-Columbia
    • Missouri Technology Expo (MU)
    • Missouri Technology Expo 2010 (MU)
    • Abstracts (Missouri Technology Expo 2010)
    • View Item
    •   MOspace Home
    • University of Missouri-Columbia
    • Missouri Technology Expo (MU)
    • Missouri Technology Expo 2010 (MU)
    • Abstracts (Missouri Technology Expo 2010)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    advanced searchsubmit worksabouthelpcontact us

    Browse

    All of MOspaceCommunities & CollectionsDate IssuedAuthor/ContributorTitleIdentifierThesis DepartmentThesis AdvisorThesis SemesterThis CollectionDate IssuedAuthor/ContributorTitleIdentifierThesis DepartmentThesis AdvisorThesis Semester

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular AuthorsStatistics by Referrer

    Targeted antisense radiotherapy [abstract]

    Lewis, Michael R.
    Balkin, Ethan
    View/Open
    [PDF] TargetedAntisenseRadiotherapy[abstract].pdf (38.55Kb)
    Date
    2010-10
    Format
    Abstract
    Metadata
    [+] Show full item record
    Abstract
    Cancer is the one of the leading causes of death worldwide. While huge strides have been made in the treatment of various cancers, there is still a critical need for effective therapeutics that only target and kill the cancer cells while not affecting other cells in the body. The current invention developed by researchers at the University of Missouri is a novel agent for simultaneous, targeted gene and radiation therapy of blood cancers. The agent binds selectively to non-Hodgkin's lymphoma (NHL) cells and contains an antisense module that reduces the activity of a cancer gene to sensitize tumors to radiation. Simultaneously, the agent delivers radiation that is highly efficient at killing these sensitized cancer cells. Our invention is superior to conventional targeted radiotherapy because its two simultaneous mechanisms of action work together to ensure better cancer cell killing, potentially giving it more efficacy than existing approaches. Potential Areas of Applications: * Treatment of blood cancer * Can be modified to treat other cancers Patent Status: Provisional patent application cover sheet on file - 10UMC069prov Inventor(s): Michael Lewis, Ethan Balkin Contact Info: Harriet F. Francis, MS; J.D. francish@missouri.edu 573-884-0374 Per Stromhaug, Ph.D., MBA stromhaugpe@missouri.edu 573-884-3553
    URI
    http://hdl.handle.net/10355/9790
    Part of
    Abstracts (Missouri Technology Expo 2010)
    Collections
    • Abstracts (Missouri Technology Expo 2010)

    Send Feedback
    hosted by University of Missouri Library Systems
     

     


    Send Feedback
    hosted by University of Missouri Library Systems